Emergent BioSolutions Inc (EBS) Quote| Reuters.com
United States

Emergent BioSolutions Inc (EBS)

EBS on New York Consolidated

24 Jun 2016
Change (% chg)

$-1.31 (-4.27%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for EBS


Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of... (more)


Beta: 1.38
Market Cap(Mil.): $1,175.38
Shares Outstanding(Mil.): 40.06
Dividend: --
Yield (%): --


  EBS Industry Sector
P/E (TTM): 15.90 38.82 34.11
EPS (TTM): 1.85 -- --
ROI: 9.91 -5.72 14.23
ROE: 14.67 -4.83 15.46

BRIEF-FDA Accepts Emergent BioSolutions' supplemental biologics license application for large-scale manufacturing of BioThrax in Building 55

* FDA has set a prescription drug user fee act (PDUFA) target action date of august 15, 2016

Jun 17 2016

BRIEF-Emergent Biosolutions Inc receives FDA orphan drug status for BioThrax

* Emergent BioSolutions Inc receives FDA orphan drug status for BioThrax for post-exposure prophylaxis of anthrax disease

Jun 15 2016

BRIEF-Emergent Biosolutions reports Q1 GAAP earnings per share $0.10

* Emergent biosolutions reports first quarter 2016 financial results

May 05 2016

BRIEF-Emergent Biosolutions submits application for large scale manufacturing of biothrax

* Submits Sbla For Fda Approval Of Large Scale manufacturing of biothrax in building 55

Apr 18 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Provider : Pechala's Reports
Provider : Reuters Investment Profile
Provider : New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.